Hormone receptor positive (HR +), human epidermal growth factor receptor‐2–negative (HER2–) breast cancer subtype, comprises more than 70% of metastatic breast cancers (MBC) [2, 3]. This evidence concerns the gene ERBB2 and breast cancer.